TY1A-DR4 Antibody

What is the molecular target of DR4 antibodies?

DR4 antibodies target the tumor necrosis factor receptor superfamily member 10A (TNFRSF10A), commonly known as death receptor 4 (DR4). This receptor is a type I transmembrane protein expressed in most human tissues, particularly in spleen, peripheral blood leukocytes, and thymus, as well as in various tumor-derived cell lines . DR4 contains an extracellular domain that binds to TRAIL, a transmembrane domain, and an intracellular death domain that mediates apoptosis signaling. When activated, DR4 recruits FAS-associated protein with death domain (FADD) and caspase-8 to form a death-inducing signaling complex (DISC), initiating the apoptotic cascade .

How do different DR4 antibody clones compare in their epitope recognition?

Different DR4 antibody clones vary in their epitope recognition, which affects their functional properties. For example, antibodies like DR-4-02 recognize specific extracellular epitopes of TRAIL-R1 (DR4) , while others may target different domains of the receptor. Mapatumumab (HGS-ETR1 or TRM1), the only anti-DR4 monoclonal antibody evaluated in clinical trials, demonstrates selective and high binding to DR4 . Other research antibodies include mouse monoclonal antibodies such as m921/922, 4H6/4G7, AY4, and TR1-mAbs, each with different binding characteristics and potential for inducing apoptosis . When selecting an antibody for research, it's crucial to consider the specific epitope recognition pattern as it directly influences the antibody's agonistic properties and effectiveness in inducing apoptosis.

What are the recommended applications for DR4 antibodies in research settings?

DR4 antibodies are versatile tools with multiple applications in research settings:

For optimal results, researchers should consider sample-dependent titration, as the appropriate concentration may vary based on cell type and experimental conditions . Additionally, DR4 antibodies can be used in immunohistochemistry to detect DR4 expression in tissue samples and in apoptosis assays to investigate TRAIL-induced cell death mechanisms.

How should researchers optimize DR4 antibody performance in Western blot analyses?

Optimizing DR4 antibody performance in Western blot analyses requires careful consideration of several factors:

• Sample preparation: DR4 has an expected molecular weight of approximately 50 kDa, but is typically observed between 37-55 kDa due to post-translational modifications, particularly glycosylation . Complete cell lysis and protein denaturation are crucial for accurate detection.

• Blocking conditions: PBS with 0.02% sodium azide and 50% glycerol at pH 7.3 is typically recommended for storage . For blocking during the Western blot procedure, use 5% non-fat dry milk or BSA in TBST.

• Antibody dilution: Start with the manufacturer's recommended dilution (e.g., 1:2000-1:12000 for polyclonal antibodies like 24063-1-AP) and adjust based on signal intensity and background.

• Positive controls: Include positive control samples such as lysates from A549, Jurkat, HeLa, or PC-3 cells, which have been validated to express detectable levels of DR4 .

• Detection method: Secondary antibody selection should match the host species of the primary antibody. HRP-conjugated secondary antibodies with enhanced chemiluminescence (ECL) provide sensitive detection.

• Membrane stripping considerations: If membrane stripping is necessary, use mild stripping conditions to avoid damaging the epitopes recognized by the DR4 antibody.

What controls should be included when using DR4 antibodies in experimental designs?

When designing experiments with DR4 antibodies, the following controls should be included:

• Positive controls: Cell lines with known DR4 expression, such as A549, Jurkat, HeLa, and PC-3 cells . These validate that the antibody is functioning properly.

• Negative controls:

  • Isotype controls matched to the DR4 antibody class (e.g., IgG2b κ for some monoclonal antibodies)

  • Cell lines with low or no DR4 expression

  • DR4 knockout or knockdown samples where available

• Specificity controls:

  • Pre-absorption with the immunizing peptide to confirm specific binding

  • Secondary antibody only controls to assess non-specific binding

  • Cross-reactivity assessment with other TRAIL receptors like DR5

• Functional controls:

  • When studying apoptosis induction, include TRAIL as a positive control

  • For blocking experiments, include untreated controls and TRAIL-only treated samples

• Technical controls:

  • Loading controls for Western blot (e.g., β-actin, GAPDH)

  • Unstained and single-stained controls for flow cytometry

  • Titration series to determine optimal antibody concentration

How do post-translational modifications of DR4 affect antibody recognition and functional outcomes?

Post-translational modifications, particularly glycosylation, significantly impact DR4 antibody recognition and functional outcomes. N-glycosylation of DR4 has been found to be essential for proper receptor aggregation and execution of apoptosis through recruitment of the TRAIL death-inducing signaling complex (DISC) machinery .

The observed molecular weight variability of DR4 (37-55 kDa compared to the calculated 50 kDa) is primarily attributed to these glycosylation patterns . Researchers should be aware that:

• Differential glycosylation across cell types can affect epitope accessibility and antibody binding efficiency

• Some antibody clones may be more sensitive to glycosylation status than others

• Deglycosylation treatments (e.g., with PNGase F) prior to Western blot analysis can help distinguish between glycosylation-dependent and independent antibody recognition

• Changes in glycosylation patterns in cancer cells may alter DR4 antibody binding and therapeutic efficacy

For research focusing on DR4 functionality, it's critical to consider how these post-translational modifications might influence experimental outcomes, particularly when comparing results across different cell types or tissue samples. Altered glycosylation in cancer cells may serve as a mechanism of resistance to TRAIL-induced apoptosis and could potentially impact the efficacy of therapeutic DR4 antibodies .

What are the mechanistic differences between DR4 and DR5 antibodies in inducing apoptosis?

While both DR4 and DR5 antibodies can induce apoptosis, important mechanistic differences exist that researchers should consider:

• Receptor aggregation dynamics: Both DR4 and DR5 antibodies induce receptor clustering, but recent evidence indicates that DR4 is superior to DR5 in transducing apoptosis upon TRAIL binding and when TRAIL is functionalized to nanoparticles . This suggests different thresholds for activation or differences in downstream signaling efficiency.

• DISC formation kinetics: The composition and assembly rate of the death-inducing signaling complex may differ between DR4 and DR5-mediated pathways, affecting the speed and efficiency of apoptosis induction.

• Intracellular signaling cascades: While both receptors recruit FADD and caspase-8, the strength of activation and potential crosstalk with other signaling pathways may differ.

• Tissue-specific effectiveness: The relative importance of DR4 versus DR5 in inducing apoptosis varies across tissue types and cancer cells, with some cancers showing preferential response to DR4 targeting.

• Resistance mechanisms: Cancer cells may develop distinct resistance mechanisms against DR4 versus DR5-mediated apoptosis, including differential regulation of decoy receptors or intracellular inhibitors.

These differences have significant implications for therapeutic development, raising questions about whether antibody derivatives should target one or both receptors for optimal efficacy . Researchers investigating apoptosis pathways should carefully consider which death receptor to target based on the specific cellular context and research objectives.

How can researchers address the variability in DR4 antibody performance across different cell lines?

Variability in DR4 antibody performance across cell lines presents a significant challenge in research. To address this:

• Comprehensive cell line characterization:

  • Quantify baseline DR4 expression levels using multiple detection methods (Western blot, flow cytometry, qPCR)

  • Assess DR4 localization (membrane surface vs. intracellular) as this affects antibody accessibility

  • Evaluate the glycosylation status of DR4 across different cell lines

• Methodological standardization:

  • Standardize cell culture conditions, as receptor expression can be affected by culture density and passage number

  • Use consistent lysis and sample preparation protocols optimized for membrane proteins

  • Implement quantitative controls to normalize results across experiments

• Antibody validation strategy:

  • Test multiple DR4 antibody clones recognizing different epitopes

  • Perform epitope mapping to understand binding characteristics

  • Validate antibodies using siRNA knockdown or CRISPR knockout controls

• Functional correlation analysis:

  • Correlate antibody binding with functional outcomes (apoptosis induction)

  • Determine if variability in antibody performance correlates with known resistance mechanisms

  • Consider using combination treatments to overcome cell line-specific resistance

By implementing these approaches, researchers can better understand the sources of variability and develop more robust experimental designs that account for cell line-specific factors affecting DR4 antibody performance.

What are the challenges in developing bispecific antibodies involving DR4 targeting?

Developing bispecific antibodies involving DR4 targeting presents several technical and biological challenges:

• Format selection considerations:

  • Various bispecific formats (TandAbs, DARTs, Fab-dsFv) require different linker strategies

  • Middle linkers between 6 to 12 residues have shown efficient production of dimeric molecules

  • For TandAbs, 9-residue linkers composed of three GGS repeats have been successfully used

• Stability and expression challenges:

  • Maintaining proper folding of both binding domains simultaneously

  • Preventing domain swapping or mispairing during expression

  • Ensuring sufficient stability for in vivo applications

• Functional optimization:

  • Balancing affinity for DR4 versus the second target

  • Preserving the pro-apoptotic function of the DR4-binding domain

  • Avoiding interference between the two binding domains

• Target selection complexity:

  • Identifying appropriate second targets (e.g., immune cell receptors for redirected killing)

  • Considering potential synergistic mechanisms (e.g., DR4 + DR5)

  • Evaluating potential antagonistic effects between pathways

• Validation challenges:

  • Developing appropriate assays to confirm dual binding

  • Assessing functional activity through both binding domains

  • Confirming enhanced efficacy compared to monospecific antibodies

Researchers can address these challenges by implementing stabilization strategies such as introducing interdomain disulfide bonds (e.g., between residues H44-L100) to generate stabilized Fv domains (Fab-dsFv) , or using covalent linkage through C-terminal cysteine residues as applied in dual-affinity retargeting (DART) proteins with optimized linkers like GGGSGGGG .

How can researchers evaluate the potential of DR4 antibodies to induce antibody-dependent cellular cytotoxicity (ADCC)?

Evaluating the ADCC potential of DR4 antibodies requires systematic assessment of multiple parameters:

• Antibody engineering considerations:

  • Fc domain selection is critical as different IgG subclasses (IgG1, IgG2, IgG3, IgG4) have varying abilities to engage Fc receptors

  • Glycoengineering of the Fc portion can enhance ADCC by altering affinity for FcγRIIIa on NK cells

  • Consider testing both wild-type and modified Fc domains to optimize ADCC activity

• In vitro ADCC assay setup:

  • Cell preparation:

    • Target cells: Cancer cell lines with validated DR4 expression

    • Effector cells: Isolated NK cells, PBMCs, or NK cell lines (e.g., NK-92)

    • Establish appropriate effector-to-target (E:T) ratios (typically ranging from 5:1 to 50:1)

  • Assay readouts:

    • Cytotoxicity measurement (51Cr release, LDH release, or fluorescent dye-based assays)

    • Flow cytometry-based assessment of target cell death

    • Real-time monitoring systems for kinetic analysis of ADCC

• Controls and benchmarking:

  • Include isotype-matched control antibodies to assess background killing

  • Use established ADCC-inducing antibodies (e.g., rituximab) as positive controls

  • Test antibodies lacking ADCC function (e.g., F(ab')2 fragments) to distinguish direct killing from ADCC

• Mechanistic confirmation:

  • Blocking FcγR receptors with specific antibodies to confirm the ADCC mechanism

  • Depletion of specific immune cell populations to identify key effector cells

  • Assessment of immune cell activation markers (CD69, CD25) and degranulation (CD107a)

• Translation to in vivo models:

  • Humanized mouse models with reconstituted human immune systems

  • Assessment of tumor regression correlated with immune cell infiltration

  • Pharmacokinetic and biodistribution studies to ensure adequate tumor targeting

This methodical approach allows researchers to comprehensively evaluate whether DR4 antibodies can effectively harness immune effector functions beyond their direct pro-apoptotic activity, which was a significant factor in the clinical development of antibodies like mapatumumab .

What factors should researchers consider when optimizing DR4 antibody concentrations for apoptosis assays?

Optimizing DR4 antibody concentrations for apoptosis assays requires careful consideration of multiple experimental parameters:

• Antibody potency factors:

  • Intrinsic agonistic activity varies between antibody clones

  • Antibody valency affects receptor clustering efficiency

  • Fc receptor binding can enhance cross-linking and signaling

• Target cell considerations:

  • Baseline DR4 expression levels (flow cytometry quantification recommended)

  • Presence of decoy receptors (DcR1, DcR2) that can compete for binding

  • Intracellular apoptotic pathway integrity (caspase-8, FADD expression)

  • Inherent resistance mechanisms (c-FLIP, XIAP, survivin expression)

• Experimental design parameters:

  • Initial titration range: Test broad concentration range (0.01-50 μg/mL)

  • Incubation time: Assess at multiple timepoints (4h, 8h, 24h, 48h)

  • Cross-linking requirements: Some antibodies require secondary cross-linking for optimal activity

  • For blocking applications: Use 2-3 μg/mL antibody, added 15 minutes before TRAIL (20-200 ng/mL)

• Multiparameter readout approach:

  Assay Type	Measurement	Timeline
  Annexin V/PI	Early/late apoptosis	4-24h
  Caspase activity	Pathway activation	2-8h
  PARP cleavage	Downstream event	8-24h
  Cell viability	End result	24-72h

• Validation strategy:

  • Compare with TRAIL as positive control

  • Include pan-caspase inhibitors to confirm apoptotic mechanism

  • Test in multiple cell lines with varying sensitivity

  • Consider combination with sensitizing agents (e.g., chemotherapy drugs)

This systematic optimization approach ensures meaningful and reproducible results when evaluating DR4 antibody-induced apoptosis.

How should researchers design experiments to distinguish between DR4 and DR5-mediated apoptosis?

Designing experiments to distinguish between DR4 and DR5-mediated apoptosis requires a systematic approach with specific controls and analytical methods:

• Receptor-specific knockout/knockdown validation:

  • Generate DR4-specific and DR5-specific knockout cell lines using CRISPR-Cas9

  • Alternatively, use siRNA or shRNA to create transient or stable knockdowns

  • Validate knockdown efficiency by Western blot and flow cytometry

  • Assess cross-compensation mechanisms (upregulation of one receptor when the other is depleted)

• Selective agonist approach:

  • Use receptor-specific agonistic antibodies:

    • For DR4: Mapatumumab or other validated DR4-specific antibodies

    • For DR5: Lexatumumab, conatumumab, or other DR5-specific antibodies

  • Compare response patterns between selective agonists and pan-TRAIL treatment

  • Include combination treatments to assess potential synergy or antagonism

• Competitive binding strategy:

  • Pre-block one receptor with non-agonistic antibodies before adding TRAIL

  • Use receptor-specific blocking antibodies at 2-3 μg/mL, 15 minutes before adding TRAIL

  • Analyze shifts in dose-response curves to quantify relative contribution

• Pathway analysis:

  • Assess DISC formation kinetics using immunoprecipitation of receptor complexes

  • Compare timing and magnitude of caspase-8 activation between receptors

  • Evaluate differences in activation of downstream signaling molecules

  • Consider non-apoptotic outcomes (NF-κB activation, pro-survival signaling)

• Signaling kinetics differentiation:

  • Time-course experiments measuring apoptotic markers

  • Single-cell analysis to identify potential heterogeneity in response

  • Computational modeling of signaling dynamics

Recent evidence suggests that DR4 is superior to DR5 in transducing apoptosis upon TRAIL binding and when TRAIL is functionalized to nanoparticles . This differential behavior should be considered when interpreting experimental results, especially in contexts where both receptors are expressed.

What methodologies can researchers use to evaluate DR4 antibody internalization and trafficking?

Evaluating DR4 antibody internalization and trafficking requires specialized techniques to track receptor-antibody complexes:

• Live-cell imaging approaches:

  • Fluorescently labeled antibodies (Alexa Fluor conjugates)

  • Time-lapse confocal microscopy to visualize internalization kinetics

  • Dual-color labeling to distinguish surface-bound from internalized antibodies

  • FRET-based approaches to detect conformational changes during trafficking

• Quantitative internalization assays:

  • Acid wash technique: Removing surface-bound antibodies with low pH buffer

  • Flow cytometry with quenchable fluorophores

  • Biotinylation-based assays to distinguish surface from internal pools

  • Radioligand internalization assays with 125I-labeled antibodies

• Subcellular localization studies:

  • Co-localization with endosomal markers:

    • Early endosomes: EEA1, Rab5

    • Late endosomes: Rab7

    • Lysosomes: LAMP1, LAMP2

  • Immunoelectron microscopy for ultrastructural localization

  • Subcellular fractionation followed by Western blotting

• Trafficking pathway investigation:

  • Pharmacological inhibitors:

    • Dynamin inhibitors (Dynasore) to block endocytosis

    • Chloroquine to prevent lysosomal degradation

    • Brefeldin A to disrupt Golgi trafficking

  • Dominant-negative constructs of trafficking regulators (Rab GTPases)

  • Temperature manipulation (4°C to block internalization)

• Functional consequences assessment:

  • Correlation between internalization rate and apoptosis induction

  • Effect of trafficking inhibitors on antibody efficacy

  • Comparison of rapidly versus slowly internalizing antibody clones

  • Development of antibody-drug conjugates leveraging internalization properties

These methodologies provide comprehensive insights into the fate of DR4 antibodies following receptor binding, which is crucial for developing effective therapeutic strategies, particularly for antibody-drug conjugates where internalization is required for payload delivery.

How can researchers assess the impact of DR4 antibodies on non-apoptotic signaling pathways?

Assessing DR4 antibody effects on non-apoptotic signaling requires comprehensive analysis beyond classical apoptosis readouts:

• NF-κB pathway activation analysis:

  • Nuclear translocation of p65/RelA by immunofluorescence or subcellular fractionation

  • IκBα phosphorylation and degradation by Western blot

  • NF-κB reporter assays using luciferase constructs

  • DNA binding activity using EMSA or ChIP assays

  • Target gene expression (IL-8, cIAP2) by qRT-PCR

• MAPK pathway assessment:

  • Phosphorylation status of:

    • ERK1/2 (p44/42)

    • JNK1/2/3

    • p38 MAPK isoforms

  • Kinase activity assays

  • Downstream transcription factor activation (AP-1, c-Jun, ATF2)

  • Correlation with cell migration/invasion phenotypes

• Pro-survival signaling evaluation:

  • PI3K/Akt pathway activation:

    • Phospho-Akt (Ser473, Thr308)

    • Phospho-GSK3β

    • FOXO transcription factor localization

  • Autophagy induction markers (LC3-I to LC3-II conversion, p62 levels)

  • Anti-apoptotic protein expression (Bcl-2, Bcl-xL, Mcl-1)

• Integrated signaling network analysis:

  • Phosphoproteomic profiling before and after antibody treatment

  • Reverse-phase protein arrays for multiple pathway components

  • Systems biology approaches to model pathway crosstalk

  • Single-cell signaling analysis to detect heterogeneous responses

• Functional consequence studies:

  • Cell migration assays (wound healing, transwell)

  • Invasion assays with matrigel barriers

  • Cytokine/chemokine secretion profiles (multiplex assays)

  • Long-term survival under stress conditions

This comprehensive approach is important as DR4, like other death receptors (Fas, TNFR1), can mediate NF-κB activation in addition to apoptosis . Understanding these non-apoptotic effects is crucial as they may influence therapeutic outcomes and potentially promote undesired effects like increased cell motility or metastasis in certain contexts .

What strategies can researchers employ to enhance the stability and shelf-life of DR4 antibodies?

Maximizing DR4 antibody stability and shelf-life is crucial for research reproducibility and therapeutic applications:

• Optimal storage buffer formulation:

  • Standard buffer composition:

    • PBS with 0.02% sodium azide and 50% glycerol at pH 7.3

    • Alternative: PBS with 5-15% trehalose or sucrose as cryoprotectants

  • pH optimization: Typically 7.2-7.4 for maximal stability

  • Addition of stabilizers:

    • Polysorbates (Tween 20/80) at 0.01-0.05% to prevent aggregation

    • Human serum albumin (HSA) or BSA (0.1-0.5%) for protein stabilization

    • Antioxidants (methionine, ascorbic acid) to prevent oxidation

• Physical stability enhancement:

  • Aliquoting recommendations:

    • Store in small single-use aliquots to avoid freeze-thaw cycles

    • Use low-protein binding tubes (polypropylene)

  • Temperature considerations:

    • Long-term storage at -20°C or -80°C

    • Avoid storage at 2-8°C for periods exceeding one week

    • Thawing protocols: Gentle thawing at room temperature, avoid heat

  • Light protection: Amber vials or aluminum foil wrapping, especially for fluorescently labeled antibodies

• Chemical stability monitoring:

  • Analytical techniques:

    • Size-exclusion chromatography to detect aggregation

    • Cation-exchange chromatography for charge variant analysis

    • Mass spectrometry to identify chemical modifications

  • Critical quality attributes to monitor:

    • Oxidation of methionine residues

    • Deamidation of asparagine and glutamine

    • Fragmentation through hydrolysis

    • Disulfide bond reduction or scrambling

• Functional stability assessment:

  • Binding activity testing:

    • ELISA against recombinant DR4

    • Flow cytometry with DR4-expressing cell lines

  • Functional activity:

    • Apoptosis induction capacity over time

    • Western blot recognition consistency

• Alternative stabilization approaches:

  • Lyophilization with appropriate cryoprotectants

  • Antibody fragmentation (Fab, F(ab')2) for applications where Fc is not required

  • Surface modification (PEGylation) for therapeutic applications

  • Formulation at higher concentrations (>1 mg/mL) to reduce surface adsorption losses

By implementing these strategies, researchers can maintain DR4 antibody quality through extended storage periods, ensuring consistent and reproducible experimental results.